Currently, only one drug targeting MAC downstream of C5 has progressed to clinical trials; AAVCAGsCD59 is a gene therapy agent in development for age-related macular degeneration (AMD); the agent is injected into the eye to locally express a non-anchored form of the MAC inhibitor CD59 (8). This evidence concerns the gene CD59 and age-related macular degeneration.